

References

1. **Amre DK, Lu SE, Costea F and Seidman EG (2006):**
Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients.
Am J Gastroenterol.; 101(3):645-52.
2. **Aldebert D, Masy E, Reumaux D, Lion G, Colombel JF and Duthilleul P (1997):**
Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis or Crohn's disease.
Dig Dis Sci.; 42(11):2350-5.
3. **Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B and Colombel JF (2001):**
Familial expression of anti-Sa. ccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis.
Am J Gastroenterol; 96: 2407-2412
4. **Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF and Andriulli A (2004):**
Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
Aliment Pharmacol Ther.; 20(10):1143-52.
5. **Baert F, Weuters K, Z, Heans G, Hoang P, Naegels S and Heygere D (1999):**
Lymphocytic colitis: a distinct clinical entity? A clinicopathological veiw on lymphocytic and collagenous colitis.
Gut; 45:375-81.
6. **Bansi DS, Chapman RW and Fleming KA (1996):**
Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Eur J Gastroenterol Hepatol.;8(9):881-5.
7. **Baron JH, Connel AM, Lennard-Jones JE:: 89-92, 1964. 2. Modigliani R, Mary JY**
Development and validation Endoscopy concordance in diagnosis of IBD
Gastroenterology; 80(2):366-74
8. **Barta Z, Csípõ I, Szabó GG and Szegedi G (2003):**
Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease.
World J Gastroenterol.; 9(10):2308-12.

9. **Bartůnková J, Kolárová I, Sedivá A and Hölzelová E (2002):**
Anti-neutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases.
Clin Immunol.; 102(2):162-8.
10. **Basu D, Lopez I, Kulkarni A and Sellin JH (2005):**
Impact of race and ethnicity on inflammatory bowel disease.
Am J Gastroenterol.; 100(10):2254-61.
11. **Becker K, Berger M, Niederau C and Frieling T (1999):**
Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
Hepatogastroenterology; 46(28):2309-14.
12. **Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ and Levi AJ (1987):**
Non-steroidal anti-inflammatory drug-induced intestinal inflammation in humans.
Gastroenterology; 93(3):480-9.
13. **Blackstone MO, Riddell RH, Rogers BH and Levin B (1981):**
Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.
Gastroenterology; 80(2):366-74.
14. **Boehme MW, Autschbach F, Zuna I, Scherbaum WA, Stange E, Raeth U, Sieg A and Stremmel W (1997):**
Elevated serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis.
Gastroenterology; 113(1):107-17.
15. **Bogomoletz WV (1994):**
Collagenous, microscopic, lymphocytic colitis. An evolving concept.
Virchows Arch; 424: 573-79.
16. **Bogomoletz WV and Flejou JF (1991):**
Newly recognized forms of colitis. Collagenous colitis, microscopic (lymphocytic) colitis and lymphoid follicular proctitis.
Semin Diagn. Pathol.; 8: 178-89.
17. **Bouma G, Oudkerk Pool M, Crusius JB, Schreuder GM, Hellemans HP, Meijer BU, Kostense PJ, Giphart MJ, Meuwissen SG and Peña AS (1997):**
Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD).
109(1):175-9.
18. **Butt JH, Konishi F, Morson BC, Lennard-Jones JE and Ritchie JK (1993):**
Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis.
Dig Dis Sci.; 28(1):18-26.

19. **Candelli M, Nista EC, Nestola M, Armuzzi A, Silveri NG, Gasbarrini G and Gasbarrini A (2003):**
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis.
J Clin Gastroenterol; 36: 39-40
20. **Catucci V, Albrizio M, Sebastiani R, Martinelli G and Florio C (1990):**
Ileal stenosis caused by chronic granulomatous inflammation secondary to a foreign body simulating Crohn disease.
Minerva Chir.; 45(6):419-24.
21. **Cawthorn SJ, Gibbs NM and Marks GG (1983):**
Antigen priming, not tolerance, with oral administration in inflammatory bowel diseases.
Gastroenterology; 110: A881.
22. **Chaldakov GN (1991):**
Leucocyte-endothelial cell interactions.
Aliment Pharmacol Ther.;5(6):665-6.
23. **Chiu G and Rajapakse CN (1991):**
Cutaneous polyarteritis nodosa and ulcerative colitis.
J Rheumatol.; 18(5):769-70.
24. **Collins WJ, Bendig DW and Taylor WF (2000):**
Pulmonary vasculitis complicating childhood ulcerative colitis.
25. **Colombel JF, Reumaux D, Duthilleul P, Noël LH, Gower-Rousseau C, Paris JC and Cortot A (1992):**
Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases.
Gastroenterol Clin Biol. 1992;16(8-9):656-60.
26. **Cosmi L, De Palma R, Santarlaschi V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, Liotta F, Maggi E, Romagnani S and Annunziato F (2008):**
Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor.
J Exp Med.;205(8):1903-16.
27. **Crags A, West S, Curtis A, Welfare M and Hudson M (2001):**
Absence of association between IL-1RN and IL-1B gene polymorphism in ulcerative colitis and Crohn's disease in multiple populations from Northeast England.
Scand. J. Gastroenterol.; 36(11):1173-8.
28. **Das KM (1990):**
Reactivity of aggregated immunoglobulin in Crohn's disease.
Gastroenterology; 99(3):904-5.

29. **Dassopoulos T (2001):**
Diagnostic methodologies: serology, endoscopy, and radiology.
Curr Gastroenterol Rep.;3(6):491-9.
30. **Dawson A, Gibbs AR and Anderson G (1993):**
An unusual perilobular pattern of pulmonary interstitial fibrosis associated with Crohn's disease.
Histopathology; 23(6):553-6.
31. **Dechairo B, Dimon C, van Heel D, Mackay I, Edwards M, Scambler P, Jewell D, Cardon L, Lench N and Carey A (2001):**
Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 16.
Eur J Hum Genet.; 9(8):627-33.
32. **Desplat-Jégo S, Johanet C, Escande A, Goetz J, Fabien N, Olsson N, Ballot E, Sarles J, Baudon JJ, Grimaud JC, Veyrac M, Chamouard P and Humbel RL (2007):**
Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study.
World J Gastroenterol. 2007; 13(16):2312-8.
33. **Desreumaux P and Colombel JF (2001):**
Intestinal microflora and chronic inflammatory bowel diseases.
Gastroenterol Clin Biol.; 25(2 Pt 2):C89-93.
34. **Eggena MO, Cohavy MH, Parseghian BA, Hamkalo D, Clemens SR, Targan LK and Braun J (2000):**
Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA.
J. Autoimmun. 14:83-97.
35. **Ekbom A (1999):**
Epidemiology of inflammatory bowel disease.
Nestle Nutr Workshop Ser Clin Perform Programme.; 2:7-18.
36. **Fasoli R, Talbot I, Reid M, Prince C and Jewell DP (1992):**
Microscopic colitis: can it be qualitatively and quantitatively characterized?
Ital J Gastroenterol.; 24(7):393-6.
37. **Farrell RJ and LaMont JT (2002):**
Microbial factors in inflammatory bowel disease.
Gastroenterol Clin North Am.; 31(1):41-62.
38. **Farrell RJ and Peppercorn MA (2002):**
Ulcerative colitis.
Lancet; 359(9303):331-40.

39. **Faubion WA and Sandborn WJ (2000):**
Probiotic therapy with *E. coli* for ulcerative colitis: take the good with the bad.
Gastroenterology; 118(3):630-1.
40. **Finnie IA, Dwarakanath AD, Taylor BA and Rhodes JM (1995):**
Colonic mucin synthesis is increased by sodium butyrate.
Gut; 36(1):93-9.
41. **Fiore NF, Conway JH, West KW and Kleiman MB (1998):**
Saccharomyces cerevisiae infections in children.
Pediatr Infect Dis J; 17: 1177-9.
42. **Floch MH (2003):**
Saccharomyces: is it a probiotic or a pathogen and what is the significance of an elevated anti-*S. cerevisiae* antibody?
J Clin Gastroenterol; 36: 5-6
43. **Frenzer A, Fierz W, Rundler E, Hammer B and Binek J (1998):**
Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease.
J. Gastroenterol. Hepatol. 13:863-864
44. **Forbes A, (1997)**
Secretion imbalance between tumour necrosis factor and its Results—Spontaneous secretion of TNF- α in involved IBD mucosa was high, from inflammatory bowel disease.
Gastroenterology. 1997 May;112(5):1493–1505.
45. **Geboes K and Rutgeerts P (1999):**
Dysplasia in inflammatory bowel diseases: definition and clinical impact.
Can J Gastroenterol.; 13(8):671-8. Review.
46. **Geboes K, Riddell R, Ost A, Jensfelt B, Persson T and Löfberg R (2000):**
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.
Gut; 47(3):404-9.
47. **Geboes K, El-Zine MY, Dalle I, El-Haddad S, Rutgeerts P and Van Eyken P (2001):**
Tenascin and strictures in inflammatory bowel disease: an immunohistochemical study.
Int J Surg Pathol.; 9(4):281-6.
48. **Gent AE, Hellier MD, Grace RH, Swarbrick ET and Coggon D (1994):**
Inflammatory bowel disease and domestic hygiene in infancy.
Lancet; 343(8900):766-7.

49. **Greenstein AJ, Gennuso R, Sachar DB, Heimann T, Smith H, Janowitz HD and Aufses AH Jr (1985):**
Extraintestinal cancers in inflammatory bowel disease.
Cancer;56(12):2914-21.
50. **Halfvarson J, Standaert-Vitse A, Järnerot G, Sendid B, Jouault T, Bodin L, Duhamel A, Colombel JF, Tysk C and Poulain D (2005):**
Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease.
Gut.; 54(9):1237-43.
51. **Halstensen TS and Brandtzaeg P (1991):**
Local complement activation in inflammatory bowel disease.
Immunol Res.; 10(3-4):485-92.
52. **Hamilton MI, Dick R, Crawford L, Thompson NP, Pounder RE and Wakefield AJ (1995):**
Is proximal demarcation of ulcerative colitis determined by the territory of the inferior mesenteric artery?
Lancet; 345(8951):688-90.
53. **Hanauer (1996)**
Stephen Hanauer, MD - University of Chicago Medical Center, 20 May 2009, Dr. Stephen Hanauer is a world leader in the treatment of inflammatory bowel diseases (IBD). He is the past chair of the Immunology.
54. **Hisabe T, Matsui T, Sakurai T, Murakami Y, Tanabe H, Mataka H, Yao T, Kamachi S and washita A (2003):**
Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value.
J Gastroenterol. 2003; 38(2):121-6.
55. **Hocke M, Richter L, Bosseckert H and Eitner K (1999):**
Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease.
Hepatogastroenterology; 46(28):2333-7.
56. **Iltanen S, Tervo L, Halttunen T, Wei B, Braun J, Rantala I, Honkanen T, Kronenberg M, Cheroutre H, Turovskaya O, Autio V and Ashorn M (2006):**
Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD.
Inflamm Bowel Dis.; 12(5):389-94.
57. **Jennette JC, Wilkman AS and Falk RJ (1998):**
Diagnostic value of ANCA serology.
Kidney Int.; 53: 796-8.

58. Kaila B, Orr K and Bernstein CN (2005):

The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease. *Can J Gastroenterol.*; 19(12):717-21.

59. Kanauchi O, Mitsuyama K, Homma T, Takahama K, Fujiyama Y, Andoh A, Araki Y, Suga T, Hibi T, Naganuma M, Asakura H, Nakano H, Shimoyama T, Hida N, Haruma K, Koga H, Sata M, Tomiyasu N, Toyonaga A, Fukuda M, Kojima A and Bamba T (2003):

Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. *Int J Mol Med.*; 12(5):701-4.

60. Kingham JG and Loehry CA (1982):

Selectivity of small intestinal exudate in celiac disease and Crohn's disease. *Am J Dig Dis.*; 23(1):33-8.

61. Kirsner JB, Meyers S, Maklansky D, Lindner A and Gilat T (1995):

Inflammatory Bowel Disease. In: Bockus Gastroenterology, Haubrich W, Schaffner F, Berk J (eds), 5th ed., 2: 1293-1570

62. Klebl FH, Bataille F, Berteau CR, Herfarth H, Hofstadter F, Scholmerich J and Rogler G (2003):

Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. *Inflamm. Bowel Dis.* 9:302-7.

63. Lehman (2002)

American Journal of Gastroenterology - 6-TG for IBD: Simple, In the four recent pilot studies using 6-TG for IBD. *Gastroenterology* 2002;122:A432

64. Lindberg E, Tysk C, Andersson K and Järnerot G (1988):

Smoking and inflammatory bowel disease. A case control study. *Gut*;29(3):352-7.

65. Macfarlane S, Furrie E, Kennedy A, Cummings JH and Macfarlane GT (2005):

Mucosal bacteria in ulcerative colitis. *Br J Nutr.*; 93 Suppl 1:S67-72.

66. Madsen KL (2001):

The use of probiotics in gastrointestinal disease. *Can J Gastroenterol.*; 15(12):817-22.

67. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR and Parratt D (1988):

Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. *BMJ*; 297: 1105-6.

68. **Makharia GK, Sachdev V, Gupta R, Lal S and Pandey RM (2007):**
Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci.; 52(1):33-9
69. **Mallant-Hent RC, Mooij M, von Blomberg BM, Linskens RK, van Bodegraven AA and Savelkoul PH (2006):**
Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World J Gastroenterol. 2006; 12(2):292-7.
70. **Melato M, Perazza L and Buri L (1996):**
Collagenous colitis and Crohn's disease: unrelated? Ital J Gastroenterol.; 28(7):406.
71. **Mir-Madjlessi SH, Forouzandeh B and Ghadimi R (1986):**
Ulcerative colitis in Iran: a review of 112 cases. Am J Gastroenterol.;80(11):862-6.
72. **Mokrowiecka A, Gasiorowska A and Malecka-Panas E (2004):**
Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases. Pol Merkur Lekarski.; 17 Suppl 1:22-6.
73. **Mokrowiecka A, Gasiorowska And Malecka-Panas E (2007):**
pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterology.;54(77):1443-8.
74. **Montanelli A, Mainardi E, Vagni A, Villanacci V, Zambelli C, Cestari R, Cengia P, Minelli L and Missale G (2005):**
Immunological markers anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: a helpful diagnostic tool. Minerva Gastroenterol Dietol.; 51(2):201-7.
75. **Moore MM, Fabricatorian D and Selby WS (2002):**
Assessment and relevance of enzyme-linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with inflammatory bowel disease. Intern Med J.; 32(7):349-52.
76. **Müller S, Styner M, Seibold-Schmid B, Flogerzi B, Mähler M, Konrad A and Seibold F (2005):**
Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. World J Gastroenterol.;11(44):6988-94.
77. **Murch SH, Braegger CP, Sessa WC and MacDonald TT (1992):**
High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet; 339(8790):381-5.

78. **Nada (1999)**
Pediatric Training Program, Emergency Medicine
Gut; 36(1):99-7
79. **Nakamura RM, Matsutani M and Barry M (2003):**
Advances in clinical laboratory tests for inflammatory bowel disease.
Clin Chim Acta.; 335(1-2):9-20.
80. **Nelson J, Barron MM, Riggs JE, Gutmann L and Schochet SS Jr. (1986):**
Cerebral vasculitis and ulcerative colitis.
Neurology.;36(5):719-21.
81. **Ng SC, Hart AL, Kamm MA, Stagg AJ and Knight SC (2009):**
Mechanisms of action of probiotics: recent advances.
Inflamm Bowel Dis.; 15(2):300-10.
82. **Oren R, Harats N, Polak A, Libson E and Naparstek Y (1989):**
Granulomatous colitis 10 years after presentation with isolated Crohn's gastritis.
Am J Gastroenterol.; 84(4):449-50.
83. **Oshitani N, Hato F, Suzuki K, Sawa Y, Matsumoto T, Maeda K, Higuchi K, Kitagawa S and Arakawa T (2003):**
Cross-reactivity of yeast antigens in human colon and peripheral leukocytes.
J Pathol; 199: 361-7.
84. **Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, Foldi I, Lakos G, Tumpek J, Udvardy ML, Harsfalvi J, Fischer S, Lakatos L, Kovacs A, Bene L, Molnar T, Tulassay Z, Miheller P, Veres G, Papp J; Hungarian IBD Study Group and Lakatos PL (2007):**
Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.
IBD; 13(8):984-92.
85. **Petras RE (1999):**
The significance of "adenomas" in ulcerative colitis: deciding when a colectomy should be performed.
Inflamm Bowel Dis.; 5(4):306-8.
86. **Pintér M, Pintérová KM, Drahosová M, Rejchrt S, Douda T, Tachecí I, Kopácová M and Bures J (2007):**
Significance of serum antibodies ANCA, ASCA, ABBA in diagnostics of idiopathic intestinal inflammations.
Cas Lek Cesk.;146(11):863-7.
87. **Pitcher MC, Beatty ER and Cummings JH (2000):**
The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.
Gut; 46(1):64-72.

88. **Price AB and Davies DR (1984):**
Pseudomembranous colitis.
J Clin Pathol. 1977; 30(1):1-12.
89. **Powell - Tuck 1992**
In 1992 the medical colleges of The Royal London and St Bartholomew's hospitals
Powell-Tuck, J. Major loss of body protein mass in inflammatory bowel.
Scientific Commons: J. Powell-Tuck
90. **Pullan RD, Thomas GA, Rhodes M, Newcombe RG, Williams GT, Allen A and Rhodes J (1994):**
Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis.
Gut; 35(3):353-9.
91. **Rachmilewitz D (1989):**
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
BMJ;298(6666):82-6.
92. **Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U and Rasmussen SN (1997):**
Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease.
Scand J Gastroenterol.; 32(6):604-10.
93. **Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW and Tekkis PP (2006):**
Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Am J Gastroenterol.;101(10):2410-22.
94. **Riddell RH (1985):**
Inflammatory bowel disease. Differential diagnosis and cancer of the small and large bowel.
Dig Dis Sci. 1985 Dec;30(12 Suppl):11S-13S.
95. **Riddell RH, Ransohoff DF and Levin B (1985):**
Ulcerative colitis and colonic cancer. Problems in assessing the diagnostic usefulness of mucosal dysplasia.
Dis Colon Rectum. 1985 Jun;28(6):383-8.
96. **Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O'Morain C, Ruiz-Ochoa V, Odes S, Binder V, Munkholm P, Moum B ,Stockbrügger R and Langholz E; European Collaborative Study Group on Inflammatory Bowel Disease (2007):**
The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients.
Inflamm Bowel Dis.; 13(1):24-32.

97. **Riley SA, Mani V and Goodman MJ (1991):**
Why do patients with ulcerative colitis relapse?
Gut; 32(7):832.
98. **Riquelme AJ, Calvo MA, Guzman AM, Depix MS, Garcia P, Perez C, Arrese M and Labarca JA (2003):**
Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients.
J Clin Gastroenterol; 36: 41-3.
99. **Rosa, Resnick DK, Johnson BL, Lovely TJ (1996)**
The epidemiology of inflammatory bowel disease in the Calgary, The annual age-adjusted prevalence rates rose slowly from 331 cases per 100000 in 1996 (95% CI: 374 to 398) to 381 cases per 100000 in 2002 (95% CI: 369 to 392). The crude IBD incidence rose slightly between 1999.
IBD: 15(2):300-96
100. **Rosai (1996)**
Rosai-Dorfman disease presenting with multiple orbital and intracranial masses.
Acta Neuropathol 1996;91:554-557.
101. **Sartor RB (1994):**
Cyclosporine therapy for inflammatory bowel disease.
N Engl J Med.; 330(26):1897-8.
102. **Satsangi J, Parkes M and Jewell DP (1996):**
Genetics of ulcerative colitis.
Lancet.; 348(9027):624-5.
103. **Sawyerr AM, Pottinger BE, Savage CO, Bradley NJ, Hudson M, Wakefield AJ, Pearson JD and Pounder RE (1994):**
Serum immunoglobulin G reactive with endothelial cells in inflammatory bowel disease.
Dig Dis Sci. 1994 Sep;39(9):1909-17.
104. **Sendid B, Quinton JF and Charrier G (1998):**
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease.
Am J Gastroenterol.;93:1306-10
105. **Shanahan F (1994):**
Current concepts of the pathogenesis of inflammatory bowel disease.
Ir J Med Sci.; 163(12):544-9.
106. **Shen B (2009):**
Crohn's disease of the ileal pouch: reality, diagnosis, and management.
Inflamm Bowel Dis. 2009; 15(2):284-94.

107. Shepherd NA (1996):

Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades.
Gut; 38(6):801-2.

108. Sokol H, Lepage P, Seksik P, Dore J and Marteau P (2006):

Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active *Escherichia coli* in the microbiota of patients with ulcerative colitis.
J Clin Microbiol.;44(9):3172-7.

109. Stenson IBD 1995

Helicobacter bilis-induced inflammatory bowel disease in scid mice, Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995.
Dec;102(3):448–455. ...

110. Strobel S and Mowat AM (1998):

Immune responses to dietary antigens: oral tolerance.
Immunol Today; 19: 173-81

111. Surawicz CM, Haggitt RC, Husseman M and McFarland LV (1994):

Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease.
Gastroenterology; 107(3):755-63.

112. Sutherland LR (1991):

5-Aminosalicylates for prevention of recurrence in patients with Crohn's disease: time for a reappraisal?
J Clin Gastroenterol.; 13(1):5-7.

113. Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y and Saniabadi AR (2006):

A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis.
Dig Dis Sci.; 51(11):2031-8.

114. Takahasi F, Shah HS, Wise LS and Das KM (1990):

Circulating antibodies against human colonic extract enriched with a 40 kDa protein in patients with ulcerative colitis.
Gut; 31(9):1016-20.

115. Takedatsu H, Taylor KD, Mei L, McGovern DP, Landers CJ, Gonsky R, Cong Y, Vasilias EA, Ippoliti A, Elson CO, Rotter JI and Targan SR (2009):

Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation.
Gut; 58(1):60-7.

116. Teahon K, Somasundaram S, Smith T, Menzies I and Bjarnason I (1996):

Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease.
Gut; 38(6):864-9.

117. Terjung B, Spengler U, Sauerbruch T and Worman H (2000):

Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.
Gastroenterology 119:310-322

118. Terjung B, Worman J, Herzog V, Sauerbruch T and Spengler U (2001):

Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver disease from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy.
Clin. Exp. Immunol.; 126: 37-46.

119. Toolenaar TA, Freundt I, Huikeshoven FJ, Drogendijk AC, Jeekel H and Chadha-Ajwani S (1993):

The occurrence of diversion colitis in patients with a sigmoid neovagina.
Hum Pathol.; 24(8):846-9.

120. Tysk G, Lindberg E, Jarnerot G and Myrhed B (1988):

Ulcerative colitis and Crohn's disease in unselected population of monozygotic and dizygotic twins. A study of heritability and influence of smoking.
Gut; 29:990-6.

121. Van der Heide H, van der Brandt-Gradel V, Tytgat GN, Endert E, Wiltink EH, Schipper ME and Dekker W (1988):

Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative colitis.
J Clin Gastroenterol.; 10: 169-72.

122. Vasiliauskas EA, Kam LY and Karp LC (2000):

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.
Gut; 47:487-96

123. Vergara T, Cofré P, Cifuentes S, Pulgar U, Puebla C and Velasco S (2006):

Presence of antineutrophil cytoplasmic antibodies (ANCA) and anti *Saccharomyces cerevisiae* antibodies (ASCA) among patients with ulcerative colitis
Rev Med Chil.;134(8):960-4.

124. Vernier G, Sendid B, Poulain D and Colombel JF (2004):

Relevance of serologic studies in inflammatory bowel disease.
Curr Gastroenterol Rep.; 6(6):482-7.

- 125. Vessey M, Jewell D, Smith A, Yeates D and McPherson K (1986):**
Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: findings in a large cohort study of women of childbearing age.
Br Med J (Clin Res Ed); 292(6528):1101-3.
- 126. Warren BF and Shepherd NA (1992):**
The role of pathology in pelvic ileal reservoir surgery.
Int J Colorectal Dis.; 7(2):68-75.
- 127. Weir A, Taylor-Robinson SD, Poole S, Pignatelli M, Walters JF and Calam J (1997):**
Cytoplasmic antineutrophil cytoplasmic antibody-positive vasculitis associated with ulcerative colitis.
Am J Gastroenterol.; 92(3):506-8.
- 128. Wejman J, Bielecki K, Ostrowska J, Baczuk L, Perkowska-Ptasinska A and Tarnowski W (2006):**
Pathological analysis of lesions within intestines resected due to ulcerative colitis.
Pol J Pathol.; 57(2):113-6.
- 129. Yardley JH (1985):**
Comments on comparative pathology of colonic neoplasia in cotton-top marmoset (*Saguinus oedipus oedipus*).
Dig Dis Sci.; 30(12 Suppl):126S-133S.
- 130. Yukawa M, Iizuka M, Horie Y, Yoneyama K, Shirasaka T, Itou H, Komatsu M, Fukushima and T Watanabe S (2002):**
Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis.
Int J Colorectal Dis.;17(2):70-6.
- 131. Zholudev A, Zurakowski D, Young W, Leichtner A and Bousvaros A (2004):**
Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
Am. J. Gastroenterol. 99:2235-2241.